Aurobindo Pharma Q2 net profit rises 32.5 pc to Rs 1,124-cr
Hyderabad, Nov 4 (TNT) : Aurobindo Pharma Limited on Wednesday reported a 32.5 per cent year-on-year increase in consolidated net profit to Rs 1,124 crore for the second quarter ended September 30, 2026, compared to Rs 848 crore in the corresponding quarter last fiscal.
The Hyderabad-based pharmaceutical company recorded its highest-ever quarterly revenue from operations at Rs 10,263 crore, registering a growth of 23.9 per cent over Rs 8,286 crore in the year-ago period.
EBITDA, before forex and other income, rose 28.5 per cent to Rs 2,156 crore, while the EBITDA margin improved to 21 per cent from 20.3 per cent, the company said in a release.
Formulations revenue increased 24 per cent to Rs 9,102 crore, while revenue from Active Pharmaceutical Ingredients (API) grew 21 per cent to Rs 1,162 crore.
The US market recorded a 25 per cent growth in revenue to Rs 4,555 crore, driven by base business growth, new product launches and successful integration of acquisitions.
The company launched 10 products in the US market during the quarter.
Europe revenue increased 27 per cent to Rs 3,161 crore, while Growth Markets revenue rose 16 per cent to Rs 1,026 crore. Revenue from the anti-retroviral (ARV) business stood at Rs 359 crore.
As on September 30, 2026, Aurobindo had cumulatively filed 900 abbreviated new drug applications (ANDAs) with the US Food and Drug Administration (USFDA), receiving 747 final approvals and 35 tentative approvals.
The company generated free cash flows of USD 146 million during the quarter after accounting for strategic capital expenditure and reported a net cash position, including investments, of USD 189 million.
Its research and development expenditure stood at Rs 376 crore. The company also declared an interim dividend of Rs 7 per share, with basic and diluted earnings per share at Rs 19.57.
Commenting on the performance, Vice-Chairman and Managing Director K Nithyananda Reddy said the results reflected strong business fundamentals, sustained execution and the resilience of the company’s diversified product portfolio.
He said growth was supported by healthy organic momentum across key businesses and the integration of inorganic opportunities, while the company remained focused on sustainable growth and financial discipline.
TNT KS
